- ¥18bn
- ¥16bn
- ¥2bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.14 | ||
| Price to Tang. Book | 7.21 | ||
| Price to Free Cashflow | 474.57 | ||
| Price to Sales | 7.72 | ||
| EV to EBITDA | 32.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 13.94% | ||
| Return on Equity | 11.56% | ||
| Operating Margin | 15.54% | ||
Financial Summary
| Year End 31st Mar | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 1,149.86 | 1,676.46 | 1,409.52 | 1,781.94 | 2,091.29 | n/a | n/a | 19.41% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +106.6 | +93.13 | -77.29 | +112.17 | +59.45 | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
StemCell Institute Inc is mainly engaged in the cell bank business, which separates and stores cord blood. The Company operates cell bank business from umbilical cord blood and umbilical cord, development of new treatment methods and regenerative medicine products, regenerative medicine and fertility treatment, business development and investment in childbirth and childcare areas. The Company operates Cell Bank business segment. After signing the contract for the separation and storage of umbilical cord blood with customers (pregnant women), the umbilical cord blood collected at domestic umbilical cord blood collection cooperative hospitals (university hospitals, obstetric clinics and others) is collected, and carried into its cell processing center in Minato-ku, Tokyo and Midori-ku, Yokohama. It is stored at its cell storage center (Midori-ku, Yokohama, Kanagawa) for a long time at ultra-low temperature after stem cells contained in cord blood being separated, extracted and prepared.
Directors
- Last Annual
- March 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- August 5th, 1999
- Public Since
- June 25th, 2021
- No. of Shareholders
- 1,748
- No. of Employees
- 92
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 10,246,554
- Address
- Matsuoka Tamuracho Bldg., MINATO-KU, 105-0001
- Web
- https://www.stemcell.co.jp/
- Phone
- +81 368113230
- Auditors
- KPMG AZSA LLC
Upcoming Events for 7096
Full Year 2024 StemCell Institute Earnings Release
StemCell Institute Annual Shareholders Meeting
StemCell Institute Annual Shareholders Meeting
Q1 2025 StemCell Institute Inc Earnings Release
Q1 2025 StemCell Institute Inc Earnings Release
Similar to 7096
Advantage Risk Management Co
Tokyo Stock Exchange
AHC
Tokyo Stock Exchange
Amvis Holdings
Tokyo Stock Exchange
Artra
Tokyo Stock Exchange
As Partners Co
Tokyo Stock Exchange
FAQ
What is the StemCell Institute share price?
As of Today at 19:20 UTC, shares in StemCell Institute are trading at ¥1,805. This share price information is delayed by 15 minutes.
How has the StemCell Institute share price performed this year?
Shares in StemCell Institute last closed at ¥1,805 and the price had moved by -19.63% over the past 365 days. In terms of relative price strength the StemCell Institute share price has underperformed the Nikkei 225 Index by -42.63% over the past year.
What are the analyst and broker recommendations for StemCell Institute?
The overall consensus recommendation for StemCell Institute is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the StemCell Institute dividend yield?
StemCell Institute does not currently pay a dividend.
Does StemCell Institute pay a dividend?
StemCell Institute does not currently pay a dividend.
When does StemCell Institute next pay dividends?
StemCell Institute does not currently pay a dividend.
How do I buy StemCell Institute shares?
To buy shares in StemCell Institute you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of StemCell Institute?
As of the previous close price of ¥1,805, shares in StemCell Institute had a market capitalisation of ¥18bn.
Where are StemCell Institute shares listed?
Here are the trading details for StemCell Institute:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 7096
What kind of share is StemCell Institute?
Based on an overall assessment of its quality, value and momentum StemCell Institute is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a StemCell Institute share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the StemCell Institute share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like StemCell Institute. Over the past six months, its share price has underperformed the Nikkei 225 Index by -36.9%.
As of the last closing price of ¥1,805, shares in StemCell Institute were trading -22.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the StemCell Institute PE Ratio?
The StemCell Institute PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥1,805.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of StemCell Institute?
We do not have data on StemCell Institute's directors